Annual Report

Overview

The report describes Balaxi Pharmaceuticals' resilience during FY24 despite severe Angola currency volatility, while revenue declined to INR 241.29 crore. It highlights 960 registered products across eight countries and continued expansion in Africa and Latin America. The report also describes progress on the company's first pharmaceutical formulation facility in Hyderabad, expected to become operational in the first quarter of FY26. A dedicated BRSR section provides employee, governance and environmental disclosures.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023-2024
Period: Ends 31 March 2024
Publication date: 29 May 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services